Navigation Links
PAREXEL International To Present At Goldman Sachs Emerging Growth Conference
Date:11/7/2013

BOSTON, Nov. 7, 2013 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the Goldman Sachs Emerging Growth Conference on Thursday, November 14, 2013, in New York.  Josef von Rickenbach, Chairman and Chief Executive Officer, will be making a presentation on PAREXEL and discussing business developments at 11:20 a.m. ET.

A live webcast of the presentations will be available through the "Investors" section of PAREXEL's website at www.PAREXEL.com in the Upcoming Events portion of the main page, and a replay of the presentation will be available on the website until February 14, 2014.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 77 locations in 51 countries around the world, and has approximately 14,975 employees.  For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL, P
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
2. PAREXEL International to Present at J.P. Morgan Healthcare Conference
3. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
4. PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs
5. PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium
6. PAREXEL International To Present At Goldman Sachs Healthcare Conference And Jefferies Healthcare Conference
7. PAREXEL International Reports First Quarter Fiscal Year 2013 Results
8. PAREXEL International to Present at Morningstar Conference
9. PAREXEL Announces Date of Third Quarter Fiscal Year 2013 Earnings Release and Conference Call
10. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
11. PAREXEL International Announces Acquisition of HERON Group LTD, A Leading Commercialization Consultancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Vermillion, Inc. (Nasdaq:   VRML), a ... today that investors including Oracle Investment Management, ... several Vermillion directors have agreed to purchase approximately ... stock and warrants to purchase unregistered shares of ... Under the terms of the private ...
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Calif., Jun. 2 The following release was,issued today by ... Trustee of the New York State Common Retirement Fund, the ... UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ... INC. (NYSE: MCK ) SECURITIES LITIGATION, Master File ...
... Entry of its Wound Care Products, RICHMOND, Virginia ... a provider of innovative solutions for advanced,chronic wound management, ... funding of US $4 million. The round was extended ... $4 million and was led by,Eli Gilboa from Gilboa&Licht, ...
... Journal of Clinical Oncology Proves Accurate, Measurement of ER ... ... CITY, Calif., June 2 Genomic Health,Inc. (Nasdaq: GHDX ... results of a study confirming RT-PCR by Oncotype DX can,deliver ...
Cached Biology Technology:Notice of Initial Distribution of Net Settlement Funds 2Notice of Initial Distribution of Net Settlement Funds 3EnzySurge, Maker of DermaStream(TM), Completes Funding Round of US$4 Million 2EnzySurge, Maker of DermaStream(TM), Completes Funding Round of US$4 Million 3Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores 2Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores 3Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores 4
(Date:11/21/2014)...  Earlier this year Donald Spector , Chairman ... of the most prolific inventors in the world, got ... Smartphones to third party agencies. Spector envisioned this technology ... the earliest known patents in this area. Now major ... child care, elder care and hospital applications. This technology ...
(Date:11/21/2014)...   Atmel® Corporation (NASDAQ: ATML ... technology solutions, today launched the industry,s first family of ... V cc range from 1.7V to 5.5V. The ... 2 C bus communication speeds, and are available with ... ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/18/2014)... 17, 2014 The Parenteral Drug Association (PDA) today ... will speak and at least seven more will participate in ... Omni Shoreham Hotel in Washington D.C. , ... have significant support from the regulatory agencies in ... in our effort to help advance the use of ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... (DOE) has announced plans to fund research at the ... on technologies that would help reduce greenhouse gas emissions ... of carbon dioxide (CO2). The project is in collaboration ... Funded by the DOE through the 2009 American ...
... butterfly wings has inspired a 3.2m, three-year research project ... security, energy and the environment. The University of Exeter ... collaborative contract to develop new technologies based on groundbreaking ... years a team of physicists from the University of ...
... and industry leaders from around the world will gather ... Targets and Cancer Therapeutics International Conference, which will feature ... "Cancer is a complex disease and to treat ... activity that takes place at the molecular level," said ...
Cached Biology News:UAB, partners seek safe carbon dioxide storage for 'greener' power generation 2UAB, partners seek safe carbon dioxide storage for 'greener' power generation 3£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2
... Norgens Milk Bacterial DNA Isolation Kit ... and purification of genomic DNA from the ... kit allows for the isolation of genomic ... positive bacteria in milk samples. ,Purification ...
... Tissue Arrays are intended for laboratory research ... fixed in neutral buffered formalin and embedded ... was performed by certified pathologists. Tissue ... and relocated into a new recipient paraffin ...
... contains all the reagents required for a ... reductase activity in cell and tissue extracts ... It has been tested on samples prepared ... brain, spleen, and heart muscle from several ...
... Strain Competent Cell Sets Sets of ... combinations The most common method ... coli is to use chemically competent ... in the laboratory, greater efficiency, reproducibility and ...
Biology Products: